V2 Loop Peptide Elicits Broadly Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccine approaches have failed to induce a strong, broadly neutralizing antibody response against diverse HIV-1 strains, as targeting conserved regions of the HIV-1 envelope protein, particularly the gp120, has not proven protective.
Innovation Solution
Development of an isolated immunogenic peptide mimicking the V2 loop fragment of the HIV-1 surface envelope glycoprotein gp120, which can elicit anti-HIV-1 antibodies by binding specifically with antibodies in vaccinated individuals, and its incorporation into a vaccine composition with an immunogenic scaffold protein to enhance immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conserved regions of HIV-1 envelope protein gp120 are targeted for vaccine development, then broadly reactive antibodies are expected to be induced, but protective neutralizing antibody response is not achieved
Solution Approach 1:
The patent segments the V2 loop region into specific conserved epitopes (positions 165-178) that are critical for maintaining both broad reactivity and protective neutralization capability. By isolating and focusing on this specific segment rather than using the entire conserved region, the vaccine achieves both broad antibody response and protective efficacy.
Solution Approach 2:
The patent applies local quality by focusing on the specific local region of the V2 loop (amino acids 165-178) that contains the critical conserved epitopes. This localized approach identifies the precise area within the conserved region that drives both broad reactivity and protective neutralization, rather than treating the entire conserved region uniformly.
2Reliability
If variable regions of HIV-1 envelope protein are targeted, then strain-specific immunity is achieved, but cross-protection against diverse HIV-1 strains is lost
Solution Approach 1:
The patent achieves universality by identifying conserved epitopes in the V2 loop that are present across multiple HIV-1 strains and subtypes. These conserved epitopes serve as universal targets that elicit antibodies capable of recognizing and neutralizing diverse strains, thereby achieving both strain-specific immunity and cross-protection simultaneously.
3Productivity
If conventional gp120 immunogens are used in vaccine trials, then immunogenicity is achieved, but protective efficacy is not demonstrated
Solution Approach 1:
The patent extracts the critical protective epitopes from the broader V2 loop region, specifically isolating amino acids 165-178 that are responsible for protective neutralization. By taking out only these essential epitopic elements and presenting them in a optimized format, the vaccine achieves both high immunogenicity and protective efficacy.
Solution Approach 2:
The patent applies parameter changes by modifying the presentation of the V2 loop epitopes through cyclization and fusion to scaffold proteins. These structural and chemical parameter changes enhance the immunogenicity and protective efficacy of the peptide, transforming it from a non-protective conventional immunogen to a highly effective vaccine candidate.
Data Source
AI summary
The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.